3 Biotech Companies that Remain Attractive

Published Thu, 03 Sep 2015 10:30 CET by DividendYields.org

One of the fastest-developing industries in the financial markets is biotechnology. One of the biggest challenges that the biotech companies face is high R&D costs and the need for a steady revenue stream to finance their operating activities while waiting for FDA drug approval. This makes them heavily reliant on the public markets to finance the development and manufacturing of innovative medicines.
On the upside, the biotech sector remains attractive for retail investors in spite of its high-risk. According to McKinsey, in December 2014, biotech companies accounted for the 20% of the entire pharma market with global revenues of $163 billion, while their annual growth rate was +8%, double than conventional pharmaceutical companies.
This article summarizes three mid and large-cap stocks trading in the Healthcare sector of the Biotechnology industry. Having revisited their strategies and focusing on R&D, all three companies are expected to continue to grow at a fast rate, paying higher dividends to retail investors.

Baxter, Bio-Techne and Gilead Sciences Price Performance vs. S&P 500 Year over Year Graph
Baxter International (NYSE: BAX) engages in the development, manufacturing and marketing of products for the cure of immune diseases as well as chronic and severe medical conditions. The most important milestone of the Deerfield-based biotech company in July 2015 was the corporate spin-off of the bioscience sector and the creation of Baxalta (NYSE: BXLT), a separate company that develops medicines for rare diseases and focuses on gene therapy. Baxter’s D/E ratio is below 2, however, the company is dealing with debt. Q2 2015 R&D spending increased 1%, reaching $292 million, however BAX has moved $5 billion of debt to the Baxalta balance sheet and has successfully dealt with another $1.1 of convertible bonds, thus lowering interest expenses to $30 million from $42 million (YoY -28.6%). The company’s decision to bring new products to the market over the next years, aiming to improve its positioning and long-term performance, is expected to leave room for a higher dividend given its low payout ratio. A beta of 0.31 makes BAX a safe investment.

Bio-Techne Corp. (Nasdaq: TECH) is a Minneapolis-based biotech company operating in the development, manufacturing and sale of biotech products and clinical diagnostic controls globally. The acquisition in June of Cliniqa Corporation, a company focussing on the clinical diagnostic market, is expected to boost TECH’s clinical control portfolio and improve its growth as Cliniqa has a proven track record of cash-oriented growth. In addition, the company is looking to go bigger in China, believing there is growth in the Chinese market. On the upside, TECH’s acquisition strategy is expected to create profitable opportunities that could boost profitability. On the downside, sharp fluctuations in the foreign exchange rates have reduced inventories in overseas markets, namely Japan and the Pacific, thus raising a red flag for TECH. The EPS of $1.28 is expected to average at $4.27 over the next 4 years, whereas the 5-years long-term annual growth is expected 12.5%. TECH’s D/E ratio of 0.23, far below 2, indicates that the company is not relying on debt financing, which is also reflected in the low payout ratio. A beta of 0.72 suggests a safe investment.

Name Price ($) 52 wk low 52 wk high 52 wk low % 52 wk high % Market Cap ($ b) P/E D/E Beta Payout Ratio
Baxter 37.23 34.50 43.44 7.91% -14.30% 20.31 9.30 1.44 0.31 12%
Bio-Techne 91.95 86.01 114.56 6.91% -19.74% 3.42 31.82 0.23 0.72 44%
Gilead Sciences 101.49 85.95 123.37 18.08% -17.74% 148.95 10.71 0.84 0.86 18%

Gilead Sciences (Nasdaq: GILD), headquartered in Foster City, CA, engages in the development and sale of innovative medicines for HIV and chronic hepatitis, but also cardiovascular and respiratory diseases and cancer. Q2 2015 U.S revenue reported 16% YoY growth reaching $5.6 billion, while European revenue reported 50% YoY growth in spite of the foreign exchange headwinds. The growth was driven by the launch of Harvoni hepatitis medicine across various markets around the world, the sustained growth of Sovaldi hepatitis medicine outside the U.S. and increased sales of GILD’s newer HIV single-tablet regimen. GILD’s highly differentiated product line and addition of new patients to its treatment program are both expected to improve its position and boost its growth. Analyst consensus estimates an average annual growth of 13.5% over the next five years and an average EPS of $11.26 up to 2016 (current EPS $9.53). A beta of 0.84 suggests a safe investment, leaving for a higher dividend (currently at $1.72) and long-term value for investors.
Stock name Dividend Yield
Gilead Sciences 3.30
Baxter International 1.08
Techne 0.78

Articles featuring Gilead Sciences (GILD):

A Real Dividend Growth Machine: 2018 Portfolio Review

Introduction The purpose of this article is to review my investing progress in 2018, which was my seventh full year as a dividend growth investor. I follow a value-oriented dividend growth investing strategy that involves buying attractively valued stocks of companies that consistently pay and grow their dividends. My investing strategy is guided by two overarching goals: Build a sustainable and rising dividend income stream that beats inflation. I seek to achieve this goal by... Read more

Jane's FY-2018 Dividend Income Totals - Why Being Patient Pays

Investment Thesis Being told to "be patient" is something no human wants to hear and there is probably no other aspect of life where you hear it more than when it comes to the world of personal finance. I'd like to think that I've learned patience in my 29 years on this earth, but I feel like this is one of those areas where there is always room for improvement. One area of life I have learned to be patient is anything regarding finances. I've learned that... Read more

Dividend Income Update December 2018

The start of every month is exciting for all dividend income investors as we look back at the previous month and see how much passive dividend income our portfolios generated. December was exciting as ever as my year over year numbers continue to highlight the trifecta magic of dividend investing which includes, adding fresh capital, dividend raises and basic compounding to create an ever-increasing passive income stream. Even if I stopped adding fresh capital today and every dividend stock I... Read more

Share In Healthcare And Biotech Gains With 12% Yield From This Tekla Fund

Co-produced with PendragonY for High Dividend Opportunities Defensive Nature of Healthcare and Biotech Stocks The healthcare and biotech sectors should play a role in every balanced portfolio, not only because they provide diversity, but also because of their fast growth, which is generally not dependent on the state of the economy. Companies in this sector are able to increase their revenues even during uncertain times, such as a recession. These are deemed as non-cyclical stocks, so... Read more

'Safer' Dividend NASDAQ Dogs Hunt 26.5%-59.4% Net Gains Per Broker December Targets

Actionable Conclusions (1-10): Brokers Forecast Top Ten NASDAQ "Safer" Dividend Stocks to Net 26.5% to 59.4% Gains By December, 2019 Four of the ten top yield "safer" Dividend NASDAQ stocks (with name backgrounds tinted grey in the list above) were scattered in with the top ten gainers for the coming year based on analyst 1 year target prices. Thus the yield strategy for this group as graded by analyst estimates for October turned out 40% accurate. Projections based... Read more